GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigene AG (XTER:MDG1) » Definitions » Gross Margin %

Medigene AG (XTER:MDG1) Gross Margin % : 75.72% (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Medigene AG Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Medigene AG's Gross Profit for the six months ended in Dec. 2023 was €2.25 Mil. Medigene AG's Revenue for the six months ended in Dec. 2023 was €2.97 Mil. Therefore, Medigene AG's Gross Margin % for the quarter that ended in Dec. 2023 was 75.72%.

Warning Sign:

Medigene AG gross margin has been in long-term decline. The average rate of decline per year is -3%.


The historical rank and industry rank for Medigene AG's Gross Margin % or its related term are showing as below:

XTER:MDG1' s Gross Margin % Range Over the Past 10 Years
Min: 72.77   Med: 85.25   Max: 96.4
Current: 72.77


During the past 13 years, the highest Gross Margin % of Medigene AG was 96.40%. The lowest was 72.77%. And the median was 85.25%.

XTER:MDG1's Gross Margin % is ranked better than
65.47% of 750 companies
in the Biotechnology industry
Industry Median: 60.53 vs XTER:MDG1: 72.77

Medigene AG had a gross margin of 75.72% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Medigene AG was -3.00% per year.


Medigene AG Gross Margin % Historical Data

The historical data trend for Medigene AG's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigene AG Gross Margin % Chart

Medigene AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 96.40 83.85 87.00 93.65 72.77

Medigene AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 85.42 96.78 80.41 69.91 75.72

Competitive Comparison of Medigene AG's Gross Margin %

For the Biotechnology subindustry, Medigene AG's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigene AG's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigene AG's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Medigene AG's Gross Margin % falls into.



Medigene AG Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Medigene AG's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=4.4 / 6.034
=(Revenue - Cost of Goods Sold) / Revenue
=(6.034 - 1.643) / 6.034
=72.77 %

Medigene AG's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=2.2 / 2.97
=(Revenue - Cost of Goods Sold) / Revenue
=(2.97 - 0.721) / 2.97
=75.72 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Medigene AG  (XTER:MDG1) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Medigene AG had a gross margin of 75.72% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Medigene AG Gross Margin % Related Terms

Thank you for viewing the detailed overview of Medigene AG's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Medigene AG (XTER:MDG1) Business Description

Traded in Other Exchanges
Address
Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.

Medigene AG (XTER:MDG1) Headlines

No Headlines